Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody.

It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease.

[1] PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.

[2] Nevertheless, clinical trials continue for various diseases like multiple myeloma[3] and diabetes mellitus type 1[4][5] as of July 2009[update].

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.